COMPASS THERAPEUTICS, INC. Deferred Federal Income Tax Expense (Benefit)
COMPASS THERAPEUTICS, INC. (CMPX) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2021-12-31, per its 10-K filed 2022-03-18.
Discontinued › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2022-03-18
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for the quarter ending 2020-03-31 was -$13.90K.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for the quarter ending 2019-12-31 was $1.80K, a 5.88% increase year-over-year.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for the quarter ending 2019-09-30 was $6.20K, a 3.33% increase year-over-year.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for the quarter ending 2019-06-30 was -$2.00K.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2021 was $0.00.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2020 was $0.00.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2020 was -$7.90K.
- COMPASS THERAPEUTICS, INC. deferred federal income tax expense (benefit) for fiscal 2019 was -$7.60K.
| Period end | Deferred Federal Income Tax Expense (Benefit) 0 month | Deferred Federal Income Tax Expense (Benefit) 3 month | Deferred Federal Income Tax Expense (Benefit) 6 month | Deferred Federal Income Tax Expense (Benefit) 6 month as first filed | Deferred Federal Income Tax Expense (Benefit) 9 month | Deferred Federal Income Tax Expense (Benefit) 9 month as first filed | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|---|---|---|---|---|---|
| 2021-12-31 | $0.00 10-K · filed 2022-03-18 | ||||||
| 2020-12-31 | $0.00 10-K · filed 2022-03-18 | ||||||
| 2020-03-31 | -$13.90K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08 | -$12.10K derived: sum of 2 quarters · filed 2020-06-08 | -$5.90K derived: sum of 3 quarters · filed 2020-06-08 | -$7.90K 10-K · filed 2020-06-08 | |||
| 2019-12-31 | $1.80K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14 | $8.00K derived: sum of 2 quarters · filed 2020-02-14 | $6.00K 10-Q · filed 2020-02-14 | -$7.30K derived: sum of 4 quarters · filed 2020-06-08 | |||
| 2019-09-30 | $6.20K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13 | $4.20K 10-Q · filed 2019-11-13 | -$9.10K derived: sum of 3 quarters · filed 2020-06-08 | -$7.40K derived: sum of 4 quarters · filed 2020-06-08 | |||
| 2019-06-30 | -$2.00K 10-Q · filed 2019-08-13 | -$15.30K derived: sum of 2 quarters · filed 2020-06-08 | -$13.60K derived: sum of 3 quarters · filed 2020-06-08 | -$7.60K derived: sum of 4 quarters · filed 2020-06-08 | |||
| 2019-03-31 | -$13.30K derived: 10-K 12 month − 10-Q 9 month · filed 2020-06-08 | -$11.60K derived: sum of 2 quarters · filed 2020-06-08 | -$5.60K derived: sum of 3 quarters · filed 2020-06-08 | -$7.60K 10-K · filed 2020-06-08 | |||
| 2018-12-31 | $1.70K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-02-14 | $7.70K derived: sum of 2 quarters · filed 2020-02-14 | $5.70K 10-Q · filed 2020-02-14 | -$5.70K 10-Q · filed 2019-02-14 | |||
| 2018-09-30 | $6.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2019-11-13 | $4.00K 10-Q · filed 2019-11-13 | -$4.00K 10-Q · filed 2018-11-14 | ||||
| 2018-06-30 | -$2.00K 10-Q · filed 2019-08-13 | ||||||
| 2018-03-31 | -$7.40K 10-K · filed 2019-07-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |
| Protalix BioTherapeutics, Inc. (PLX) | $0.221B | 9.87 | |
| Alpha Cognition Inc. (ACOG) | $0.185B | -6.77 | |
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Aligos Therapeutics, Inc. (ALGS) | United States | $0.238B | -0.47 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |